Tumor Suppressor Proteins
"Tumor Suppressor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
| Descriptor ID |
D025521
|
| MeSH Number(s) |
D12.776.624.776
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Proteins".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Proteins".
This graph shows the total number of publications written about "Tumor Suppressor Proteins" by people in this website by year, and whether "Tumor Suppressor Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 3 | 4 |
| 2000 | 5 | 2 | 7 |
| 2001 | 4 | 3 | 7 |
| 2002 | 3 | 3 | 6 |
| 2003 | 2 | 7 | 9 |
| 2004 | 5 | 4 | 9 |
| 2005 | 4 | 7 | 11 |
| 2006 | 4 | 1 | 5 |
| 2007 | 5 | 3 | 8 |
| 2008 | 8 | 6 | 14 |
| 2009 | 5 | 5 | 10 |
| 2010 | 6 | 8 | 14 |
| 2011 | 8 | 3 | 11 |
| 2012 | 11 | 3 | 14 |
| 2013 | 9 | 11 | 20 |
| 2014 | 8 | 5 | 13 |
| 2015 | 3 | 6 | 9 |
| 2016 | 6 | 6 | 12 |
| 2017 | 3 | 3 | 6 |
| 2018 | 2 | 4 | 6 |
| 2019 | 3 | 3 | 6 |
| 2020 | 5 | 2 | 7 |
| 2021 | 4 | 5 | 9 |
| 2022 | 2 | 4 | 6 |
| 2023 | 1 | 2 | 3 |
| 2024 | 1 | 3 | 4 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Proteins" by people in Profiles.
-
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20; 43(27):3032-3040.
-
The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma. Neurosurg Focus. 2025 08 01; 59(2):E9.
-
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol. 2025 Nov; 20(11):1615-1625.
-
Analytical validation of the Belay Vantage™ assay for evaluation of MGMT promoter methylation using enzymatically converted tumorDNA from cerebrospinal fluid. Cancer Genet. 2025 Jun; 294-295:94-98.
-
Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1/TSC2-Mutations: A Series of 4 cases and a review of the literature. Hum Pathol. 2024 Nov; 153:105680.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
PU.1 and BCL11B sequentially cooperate with RUNX1 to anchor mSWI/SNF to poise the T cell effector landscape. Nat Immunol. 2024 May; 25(5):860-872.
-
Guiding the HBO1 complex function through the JADE subunit. Nat Struct Mol Biol. 2024 Jul; 31(7):1039-1049.
-
Cortical tension promotes Kibra degradation via Par-1. Mol Biol Cell. 2024 Jan 01; 35(1):ar2.
-
Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246.